Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19，销售额$4281万 超过预估的$3902万

财报速递2025-02-27
Ligand Pharmaceuticals（纳斯达克股票代码：LGND）公布季度每股收益为$1.27，超过分析师共识预估的$1.19，高出6.72%。相比去年同期每股收益$1.38，下降了7.97%。公司季度销售额为$4281万，超过分析师共识预估的$3902万，高出9.71%。相比去年同期的$2810万，增长了52.35%。

以上内容来自Benzinga Earnings专栏，原文如下：

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 7.97 percent decrease over earnings of $1.38 per share from the same period last year. The company reported quarterly sales of $42.81 million which beat the analyst consensus estimate of $39.02 million by 9.71 percent. This is a 52.35 percent increase over sales of $28.10 million the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法